~~<i id='2A3E3CF310'><strike id='2A3E3CF310'><tt id='2A3E3CF310'><pre id='2A3E3CF310'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

focus

comprehensive

author：fashion 2025-09-27 23:53:54 - browse：8986

In this photo illustration, Farxiga, Xarelto, Entresto, and Eliquis are made available to customers at the New City Halsted Pharmacy on August 29, 2023 in Chicago, Illinois. These are 4 of 10 prescription drugs that will be subject to Medicare price negotiations under the Inflation Reduction Act. The other drugs include Jardiance, Enbrel, Januvia, Imbruvica, Stelara and Fiasp. — Scott Olson/Getty Images

WASHINGTON — The Biden administration is making its opening offers to pharmaceutical companies in its brand-new Medicare drug price negotiation program on Thursday, administration officials said. And that’s about all they said.

The offers will not be made public unless a manufacturer chooses to publicly disclose information about the talks, a senior administration official said. Companies have until March 2 to either accept the government’s offer or propose a counteroffer. The Biden administration will publish the final prices by Sept. 1 of this year after the negotiation process ends.

The negotiated prices won’t take effect until 2026.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How to save PrEP access — and even expand it
Next article： Teladoc has a new CEO, but challenges remain the same

knowledge

hotspot

leisure time

hotspot

knowledge

CTscansshowedthatthepatientinitiallyrespondedtolorlatinib(left).Buteightmonthslater,themetastaticliv

WSS

STAT Summit: GSK CEO on pharma giant's new direction

Hospital price transparency does save money, advocate argues

STAT Summit: GSK CEO on pharma giant's new direction

Will Ozempic

Statins may not be needed by millions of people, study suggests

STAT Summit: GSK CEO on pharma giant's new direction

focus

comprehensive

knowledge

Affirmative action in medical school literally saved lives

Cancer thrives by mutating. But sometimes, a mutation leaves it vulnerable

BioMarin wins approval for gene therapy to treat hemophilia A

FDA struggles to regulate food additives, sometimes for decades

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

5 takeaways from STAT's examination of Zynex Medical

The high cost of giving birth even with insurance

How faith leaders like me can help address America's obesity epidemic

Continuity nursing helped my family in our darkest PICU moments

Pharma companies must ensure equitable access to obesity drugs

hotspot

Medical device trials still don't enroll enough women, study finds

Teladoc has a new CEO, but challenges remain the same

Cheap, fast test for Zika and dengue could cost just $1

California wildfire smoke linked to 52,000 early deaths, study says

Deposition: Sackler embraced plan to conceal OxyContin’s strength

NIH tests clinical research in primary care with $30 million program

leisure time

leisure time

hotspot

knowledge